uniQure N.V. Uncategorized Contracts & Agreements

10 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Letter Agreement dated October 5, 2023, by and between Richard Porter and Corlieve Therapeutics AG
uniQure N.V.
Biotechnology
2024
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
uniQure N.V.
Biotechnology
DE
2024
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
uniQure N.V.
Biotechnology
2023
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
uniQure N.V.
Biotechnology
2022
t Equity Side Letter, effective May 17, 2021, by and between uniQure N.V. and Pierre Caloz
uniQure N.V.
Biotechnology
2021
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
uniQure N.V.
Biotechnology
2021
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
uniQure N.V.
Biotechnology
2020
113 Hartwell Avenue Lexington, Massachusetts (the Building) FIRST AMENDMENT As of November 9, 2018 (Execution Date)
uniQure N.V.
Biotechnology
2018
uniQure biopharma B.V. Paasheuvelweg 25a 1105BP Amsterdam The Netherlands
uniQure N.V.
Biotechnology
2017
(signature Lessee)
uniQure N.V.
Biotechnology
2017